Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population

Molecular Biology Reports

Volumn 39, Issue 8, 2012, Pages 7871-7880

  Sivoňová, Monika Kmeåová ^a   Dobrota, Dušan ^a   Dušenka, Róbert ^a   Waczulíková, Iveta ^b   Slezák, Peter ^c   Matáková, Tatiana ^a   Mahmoodová, Silvia ^a   Mištuna, Dušan ^a   Kliment, Ján ^a  

^a University Hospital in Martin   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

CYP17; Gene polymorphism; Prostate cancer; PSA; Slovak population

Indexed keywords

CYTOCHROME P450 17; PROSTATE SPECIFIC ANTIGEN; STEROID 17ALPHA MONOOXYGENASE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CYP17 GENE; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PSA GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SLOVAKIA; BLOOD; CAUCASIAN; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PROSTATE TUMOR;

AGED; BASE SEQUENCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SLOVAKIA; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84868632674     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1631-y     Document Type: Article

References (59)

1. Grönberg H (2003) Prostate cancer epidemiology. Lancet 361:859-864
2. Sanchez-Visconti G, Herrero L, Rabadan M, Pereira I, Ruiz-Torres A (1995) Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Mech Ageing Dev 82:19-29
3. Brawley OW, Jani AB, Master V (2007) Prostate cancer and race. Curr Probl Cancer 31:211-225
4. Khan N, Afaq F, Mukhtar H (2010) Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett 293:133-143
5. Stein QP and Flanagan JD (2010) Genetic and familial factors influencing breast, colon, prostate and lung cancers. S D Med Spec No.:16-22
6. Moorthy HK, Venugopal P (2008) Strategies for prostate cancer prevention: review of the literature. Indian J Urol 24:295-302
7. Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, et al. (2009) Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 5:1005-1013
8. Payne AH, Hales DB (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25:947-970
9. Twiddy AL, Leon CG, Wasan KM (2010) Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 28:423-437
10. Miller WL (2005) Disorders of androgen synthesis-from cholesterol to dehydroepiandrosterone. Med Princ Pract 14:58-68
11. Vis AN, Schröder FH (2009) Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU Int 104:1191-1197
12. Penning TM (2010) New frontiers in androgen biosynthesis and metabolism. Curr Opin Endocrinol Diabetes Obes 17:233-239
13. Lamont KR, Tindall DJ (2010) Androgen regulation of gene expression. Adv Cancer Res 107:137-162
14. Balk SP, Ko YJ, Bubley GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21:383-391
15. Botchorishvili G, Matikainen MP, Lilja H (2009) Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol 19:221-226
16. Schröder FH, Roobol MJ (2009) Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol 19:227-231
17. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271:6379-6388
18. Xue WM, Coetzee GA, Ross RK, Irvine R, Kolonel L, et al. (2001) Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10:575-579
19. Cohen P, Peehl D, Graves H, Rosenfeld R (1994) Biological effects of prostate specific antigen (PSA) as an IGF binding protein-3 (IGFBP-3) protease. J Endocrinol 142:407-415
20. Cramer S, Chen Z, Peehl D (1996) Prostate specific antigen cleaves parathyroid hormone-related protein (PTHrP) in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156:526-531
21. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, et al. (2005) Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 202:361-370
22. Schaid DJ, Guenther JC, Christensen GB, Hebbring S, Rosenow C, et al. (2004) Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet 75:948-965
23. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H (2007) Molecular markers for prostate cancer. Cancer Lett 249:5-13
24. Sharp L, Cardy AH, Cotton SC, Little J (2004) CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. A HuGE review. Am J Epidemiol 160:729-740
25. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S (2000) Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 36:2375-2379
26. Wang LZ, Sato K, Tsuchiya N, Yu JG, Ohyama C, et al. (2003) Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett 202:53-59
27. Wang F, Zou YF, Feng XL, Su H, Huang F (2011) CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 71:1167-1177
28. Sobti RC, Gupta L, Singh SK, Seth A, Kaur P, et al. (2008) Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet 185:78-85
29. Binnie MC, Alexander FE, Heald C, Habib FK (2005) Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 63:309-315
30. Cicek MS, Liu X, Casey G, Witte JS (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14:2173-2177
31. Hamada A, Danesi R, Price DK, Sissung T, Chau C, et al. (2007) Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 70:217-220
32. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, et al. (2002) A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11:243-247
33. Jesser C, Mucci L, Farmer D, Moon C, Li H, et al. (2008) Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer 99:1743-1747
34. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, et al. (2000) Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60:839-841
35. Allen NE, Forrest MS, Key TJ (2001) The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 10:185-189
36. Tajtakova M, Pidanicova A, Valansky L, Lachvac L, Nagy V, et al. (2010) Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer. Neoplasma 57:118-122
37. dos Santos RM, de Jesus CM, Trindade Filho JC, Trindade JC, de Camargo JL, et al. (2008) PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol 27:497-503
38. Lunn RM, Bell DA, Mohler JL, Taylor JA (1999) Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20:1727-1731
39. Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, et al. (2001) Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 10:943-947
40. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E (1999) Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9:635-639
41. Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, et al. (2001) The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 10:743-748
42. Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzl G, et al. (2000) A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 87:434-437
43. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, et al. (2001) Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 92:683-686
44. Souiden Y, Mahdouani M, Chaieb K, Elkamel R, Mahdouani K (2010) CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Cancer Epidemiol 45(10):772-774
45. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, et al. (2000) Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60:5710-5713
46. Chang B, Zheng SL, Isaacs SD, Wiley KE, Carpten JD, et al. (2001) Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer 95:354-359
47. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, et al. (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92:1130-1137
48. Madigan MP, Gao YT, Deng J, Pfeiffer RM, Chang BL, et al. (2003) CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer 107:271-275
49. Ntais C, Polycarpou A, Ioannidis JP (2003) Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12:120-126
50. Cotter MP, Gern RW, Ho GY, Chang RY, Burk RD (2002) Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate 50:216-221
51. Zmuda JM, Cauley JA, Kuller LH, Ferrell RE (2001) A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J Bone Miner Res 16:911-917
52. Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, et al. (2003) Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23:1647-1651
53. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, et al. (2007) PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28:1032-1039
54. Sävblom C, Giwercman A, Malm J, Halldén C, Lundin K, et al. (2009) Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA. Int J Androl 32:479-485
55. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, et al. (2002) Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53:88-94
56. Chiang CH, Chen KK, Chang LS, Hong C (2004) The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage ofprostate cancer. J Urol 171:1529-1532
57. Rao A, Chang BL, Hawkins G, Hu JJ, Rosser CJ, et al. (2003) Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 61:864-869
58. Salinas CA, Austin MA, Ostrander EO, Stanford JL (2005) Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 65:58-65
59. Shibahara T, Onishi T, Franco OE, Arima K, Nishikawa K, et al. (2006) A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population. Anticancer Res 26:3365-3371